Sonia Guadalupe Barreno-Rocha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sonia Guadalupe Barreno-Rocha has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Arnulfo Hernán Nava-Zavala
Unidad de Investigacion Epidemiologica y en Servicios de Salud, Centro Medico Nacional de Occidente Organo de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, Mexico
2 shared publications - Benjamín Rubio-Jurado
Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Medico Nacional de Occidente, Órgano de Operación Administrativa DesconcentradaJalisco, Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico
2 shared publications - Carlos Riebeling-Navarro
Unidad de Investigación en Epidemiología Clínica, UMAE HP, Centro Médico Nacional SXXI, IMSS, Mexico City 06720, Mexico
2 shared publications - Sandra Guzmán-Silahua
Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Medico Nacional de Occidente, Órgano de Operación Administrativa DesconcentradaJalisco, Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico
2 shared publications - David Eduardo Muñoz Gaytan
Unidad de Investigación Epidemiológica y en Servicios de Salud, CMNO OOAD, Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44340, Mexico
1 shared publication - Ernesto German Cardona-Muñoz
Department of Physiology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44360, Jalisco, Mexico
1 shared publication
Latest Publications
- Open Access
- 6 August 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (15) , 2210
Frequency of Autoantibodies on Non-Hodgkin Lymphoma
(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies. (2) Methods: A retrospective cohort study was performed from 2017 to 2019 in patients with Non-Hodgkin Lymphoma diagnosed with a biopsy. (3) Results: We included 39 patients who were newly diagnosed, untreated, and without any autoimmune disease previously reported. Thirty patients had the presence of autoantibodies (antiphospholipid antibodies, anti-cytoplasmic neutrophils antibodies, antinuclear antibodies), and nine were without autoantibodies. There were no statistical differences among groups regarding clinical, demographic, staging, and prognosis characteristics. Also, there were no differences in the outcomes of the patients after finishing chemotherapy and one year after initiating treatment. (4) Conclusions: Further investigations must be conducted regarding an extended panel of autoantibodies because the panel of autoantibodies in this study did not show a relationship between the presence and the clinical outcome of the patients.
- 6 August 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (15) , 2210
Open AccessFrequency of Autoantibodies on Non-Hodgkin Lymphoma
(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies. (2) Methods: A retrospective cohort study was performed from 2017 to 2019 in patients with Non-Hodgkin Lymphoma diagnosed with a biopsy. (3) Results: We included 39 patients who were newly diagnosed, untreated, and without any autoimmune disease previously reported. Thirty patients had the presence of autoantibodies (antiphospholipid antibodies, anti-cytoplasmic neutrophils antibodies, antinuclear antibodies), and nine were without autoantibodies. There were no statistical differences among groups regarding clinical, demographic, staging, and prognosis characteristics. Also, there were no differences in the outcomes of the patients after finishing chemotherapy and one year after initiating treatment. (4) Conclusions: Further investigations must be conducted regarding an extended panel of autoantibodies because the panel of autoantibodies in this study did not show a relationship between the presence and the clinical outcome of the patients.
- Open Access
- 8 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (8) , 4151
Antiphospholipid Antibodies and Lipids in Hematological Malignancies
One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-β2 glycoprotein I (anti-β2GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.
- 8 April 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (8) , 4151
Open AccessAntiphospholipid Antibodies and Lipids in Hematological Malignancies
One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-β2 glycoprotein I (anti-β2GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.